Informace o publikaci

Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy

Autoři	SHARMA M. SMITH E. E. PEARCE L. A. PERERA K. S. KASNER S. E. YOON B. W. AMERISO S. F. PUIG J. DAMGAARD D. FIEBACH J. B. MUIR K. W. VELTKAMP R. C. TONI D. S. SHAMALOV N. GAGLIARDI R. J. MIKULÍK Robert ENGELTER S. T. BERECZKI D. O DONNELL M. J. SAAD F. SHOAMANESH A. BERKOWITZ S. D. MUNDL H. HART R. G.
Rok publikování	2022
Druh	Článek v odborném periodiku
Časopis / Zdroj	International Journal of Stroke
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://journals.sagepub.com/doi/10.1177/17474930211058012
Doi	http://dx.doi.org/10.1177/17474930211058012
Klíčová slova	Anticoagulation; cerebral microbleeds; covert stroke; embolic stroke; ESUS; randomized clinical trial; rivaroxaban
Popis	Background Covert brain infarcts are associated with important neurological morbidity. Their incidence in patients with embolic stroke of undetermined source (ESUS) is unknown. Aims To assess the incidence of covert brain infarcts and cerebral microbleeds using MRI in a prospective substudy of the NAVIGATE ESUS randomized trial and to evaluate the effects of antithrombotic therapies. Methods At 87 sites in 15 countries, substudy participants were randomly assigned to receive rivaroxaban 15 mg daily or aspirin 100 mg daily and underwent brain MRI near randomization and after study termination. The primary outcome was incident brain infarct (clinical ischemic stroke or covert brain infarct). Brain infarcts and microbleeds were ascertained centrally by readers unaware of treatment. Treatment effects were estimated using logistic regression. Results Among the 718 substudy participants with interpretable, paired MRIs, the mean age was 67 years and 61% were men with a median of 52 days between the qualifying ischemic stroke and randomization and a median of seven days between randomization and baseline MRI. During the median (IQR) 11 (12) month interval between scans, clinical ischemic strokes occurred in 27 (4%) participants, while 60 (9%) of the remaining participants had an incident covert brain infarct detected by MRI. Assignment to rivaroxaban was not associated with reduction in the incidence of brain infarct (OR 0.77, 95% CI 0.49, 1.2) or of covert brain infarct among those without clinical stroke (OR 0.85, 95% CI 0.50, 1.4). New microbleeds were observed in 7% and did not differ among those assigned rivaroxaban vs. aspirin (HR 0.95, 95% CI 0.52-1.7). Conclusions Incident covert brain infarcts occurred in twice as many ESUS patients as a clinical ischemic stroke. Treatment with rivaroxaban compared with aspirin did not significantly reduce the incidence of covert brain infarcts or increase the incidence of microbleeds, but the confidence intervals for treatment effects were wide.